FDA kwadoro ibrutinib maka ọgwụgwọ ọrịa graft-versus-host (cGVHD) n'ime ụmụaka

Na Ọgọst 24, 2022, US Food and Drug Administration (FDA) kwadoro ibrutinib maka ọgwụgwọ ụmụaka karịrị afọ 1 nwere ọrịa graft-versus-host (cGVHD) ndị na-anata ọgwụgwọ mgbe ọgwụgwọ 1 ma ọ bụ multi-line systemic dasịrị. Ihe ngosi akwadoro bụ maka ndị ọrịa ụmụaka, yana ọnụego nzaghachi zuru oke nke 60% na izu 25, usoro ọgwụ ahụ gụnyere kapsụl, mbadamba na nkwụsịtụ ọnụ.

Ibrutinib, ọgwụ mgbochi BTK nke Pharmacyclics/Johnson & Johnson mepụtara, bụ ọgwụ mgbochi kinase nke akwadoro na mbụ maka ọgwụgwọ ọrịa leukemia lymphocytic na-adịghị ala ala yana lymphoma sel na ọrịa ndị ọzọ.

Suntech lekwasịrị anya na mmepe na mmepụta nke ọgwụ etiti na API site na iji teknụzụ akwụkwọ ndụ akwụkwọ ndụ. Ugbu a, ụlọ ọrụ anyị emepụtala ngwaahịa etiti atọ nke ibrutinib gụnyere C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, a na-ere ha niile na mmepụta ụlọ ọrụ GMP. N'ime ha, etiti nke C AS: 143900-44-1 bụ nke teknụzụ kemịkal-enzymatic mepụtara, nke nwere uru nke nchekwa gburugburu ebe obibi akwụkwọ ndụ akwụkwọ ndụ, ọnụ ahịa dị ala na ịdị mma dị elu. Nnọọ ka ị kpọtụrụ ma soro ndị ọzọ kparịta ụka!